ABIOMED, Inc. (NASDAQ:ABMD) Files An 8-K Financial Statements and ExhibitsItem 9.01
Story continues below
|99.1||Press release dated September20, 2017|
ABIOMED INC ExhibitEX-99.1 2 d448279dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure DANVERS,…To view the full exhibit click
About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.